Valeant Pharmaceuticals International (VRX) Given a $18.00 Price Target by Deutsche Bank Analysts

Deutsche Bank set a $18.00 target price on Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) in a research note published on Sunday morning. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also commented on VRX. HC Wainwright set a $17.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a report on Wednesday, August 9th. Piper Jaffray Companies set a $14.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a sell rating in a report on Wednesday, August 9th. Canaccord Genuity set a $14.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a report on Thursday, August 10th. Vetr lowered shares of Valeant Pharmaceuticals International from a strong-buy rating to a buy rating and set a $19.18 price objective on the stock. in a report on Monday. Finally, Wells Fargo & Company reissued an underperform rating and set a $8.00 price objective on shares of Valeant Pharmaceuticals International in a report on Saturday, September 30th. Five equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the company. The company has an average rating of Hold and a consensus target price of $17.43.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded up $0.50 during trading hours on Friday, reaching $17.25. 17,372,300 shares of the company’s stock were exchanged, compared to its average volume of 17,806,980. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $18.25. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. The company has a market cap of $6,013.21, a price-to-earnings ratio of 2.80, a P/E/G ratio of 0.47 and a beta of -0.22.

In other Valeant Pharmaceuticals International news, Director John Paulson bought 344,216 shares of Valeant Pharmaceuticals International stock in a transaction dated Thursday, November 16th. The shares were bought at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the purchase, the director now owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. 5.87% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the stock. Eaton Vance Management raised its position in shares of Valeant Pharmaceuticals International by 1.2% in the 2nd quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock valued at $752,000 after acquiring an additional 500 shares during the period. IFP Advisors Inc raised its position in shares of Valeant Pharmaceuticals International by 0.4% in the 2nd quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock valued at $2,220,000 after acquiring an additional 509 shares during the period. Tocqueville Asset Management L.P. raised its position in shares of Valeant Pharmaceuticals International by 3.8% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 21,914 shares of the specialty pharmaceutical company’s stock valued at $379,000 after acquiring an additional 800 shares during the period. Commonwealth Bank of Australia raised its position in shares of Valeant Pharmaceuticals International by 0.7% in the 2nd quarter. Commonwealth Bank of Australia now owns 108,806 shares of the specialty pharmaceutical company’s stock valued at $1,887,000 after acquiring an additional 800 shares during the period. Finally, Nationwide Fund Advisors raised its position in shares of Valeant Pharmaceuticals International by 1.7% in the 2nd quarter. Nationwide Fund Advisors now owns 52,400 shares of the specialty pharmaceutical company’s stock valued at $907,000 after acquiring an additional 900 shares during the period. Institutional investors and hedge funds own 49.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/04/valeant-pharmaceuticals-international-vrx-given-a-18-00-price-target-by-deutsche-bank-analysts.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply